- MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight
- MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective Weight Loss in a Phase 2 Study
- In People With Type 2 Diabetes Living With Obesity or Overweight MariTide Demonstrated up to ~17% Average Weight Loss Without a Weight Loss Plateau and Lowered Average HbA1c by up to 2.2 Percentage Points at 52 Weeks
- MariTide Delivered Substantial Improvements Across Cardiometabolic Parameters
- Amgen Announces "MARITIME," a Phase 3 Clinical Development Program in Obesity and Obesity-Related Conditions
Amgen Announced Data At 52 Weeks In Phase 2 Study With MariTide (Maridebart Cafraglutide, Formerly AMG 133) Subcutaneously Administered Monthly Or Less Frequently, Showing Up To ~20% Average Weight Loss At Week 52 Without A Weight Loss Plateau
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated